dromlakhani Optimize blood sampling conditions for PA screening
STEP 1 — Gather Information
- Record time of day, fasting status (≥8 h overnight fast), and patient posture (supine vs sitting) at blood draw.
- Note any recent food intake, caffeine, nicotine, or vigorous exercise that could influence aldosterone or renin.
- Document whether the sample was obtained in the sitting position at any time.
STEP 2 — Rule In / Rule Out
- Is the sample obtained in the sitting position (regardless of fasting or time of day)?
- Yes → proceed to Step 3 (acceptable per guideline).
- No → proceed to Step 3 (non‑ideal supine sample).
STEP 3 — Classify or Stratify
- Sitting sample: classify as acceptable for screening; no further stratification needed.
- Supine sample: classify as non‑ideal; assess fasting status and time of day:
- If fasting and early morning → ideal (proceed with standard interpretation).
- If non‑fasting or not early morning → suboptimal; flag for potential reduced sensitivity/specificity.
STEP 4 — Decide
- For acceptable (sitting) or ideal supine samples: apply standard screening cutoffs (ARR ≥ 200 or PAC/ARC ≥ 40 with PAC ≥ 60 pg/mL).
- For suboptimal supine samples: either repeat the draw under ideal conditions if clinically feasible, or proceed with screening while interpreting results with caution (consider borderline ARR/PAC values as provisionally positive and pursue individualized management).
Clinical Guardrails / Mimics / Pitfalls
- Do not rely solely on a non‑ideal supine sample to exclude PA; false‑negative risk increases.
- Avoid assuming sitting position eliminates all preanalytical influences; still control for recent meals, stress, and medications that affect renin.
- Do not ignore the preference for early‑morning supine fasting when it is readily obtainable; use it to maximize test accuracy.
Concrete Clinical Example
A 58‑year‑old hypertensive patient has blood drawn in the sitting position after a light breakfast. The clinician questions validity. According to the guideline, sitting sampling is acceptable; the sample is processed with ARR ≥ 200 and PAC ≥ 60 pg/mL cutoffs, and screening proceeds without repetition.
Source: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2022, https://www.jstage.jst.go.jp/article/endocrj/69/4/69_4_327/_article